Bloodwise is working with the National Institute for Health Research and
IQVIA to gain insights into what it’s like for patients to switch to
biosimilar medication. Biosimilars are medicines shown to be
clinically equivalent to existing biological medicines and are being developed to reduce healthcare costs and to potentially increase patient access to the biologic class of therapies.
As NHS England has made recommendations to increase the number of biosimilars used within healthcare, we are being asked to gather the views of people affected by blood cancer in order to apply these findings to the roll-out process, particularly addressing any need for increased information and support provision for patients and their loved ones when this switch is made.
The survey should take approximately 4 minutes to complete, and you will be supporting us to make a real impact on blood cancer patient care. If you would like any more details then do get in touch with us via our free Support Line on 0808 2080 888 (Monday-Friday 10am-4pm) or support@bloodwise.org.uk. Any comments you make will remain anonymous, however there is an opportunity provide your contact details at the end of the survey if you wished to get further involved in this project.